Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: Do elevated MICs always predict reduced in vivo efficacy?

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 5, 2006, Pages 1628-1632

  Griffith, David C ^a,b   Corcoran, Erik ^a,c   Lofland, Denene ^a   Lee, Angela ^a,d   Cho, Deidre ^a,d   Lomovskaya, Olga ^a   Dudley, Michael N ^a  

^a Essential Therapeutics Inc   (United States)

^b Mpex Pharmaceuticals Inc   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d Ilypsa Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; LEVOFLOXACIN; MEXAB PROTEIN; MEXCD PROTEIN; MEXEF PROTEIN; OPRJ PROTEIN; OPRM PROTEIN; OPRN PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG TRANSPORT; GENE OVEREXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PREDICTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEPSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIAL OUTER MEMBRANE PROTEINS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; GENE DELETION; GENES, BACTERIAL; MALE; MEMBRANE PROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; OFLOXACIN; PSEUDOMONAS AERUGINOSA; SEPSIS;

EID: 33646448547     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.5.1628-1632.2006     Document Type: Article

References (18)

1. Aires, J. R., T. Kohler, H. Nikaido, and P. Plesiat. 1999. Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob. Agents Chemother. 43:2624-2628.
2. Akaike, H. 1978. Posterior probabilities for choosing a regression model. Ann. Inst. Stat. Math. 30A:9-14.
3. Ambrose, P. G., D. M. Grasela, T. H. Grasela, J. Passarell, H. B. Mayer, and P. F. Pierce. 2001. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 45:2793-2797.
4. Chen, H. Y., M. Yuan, and D. M. Livermore. 1995. Mechanisms of resistance to beta-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. J. Med. Microbiol. 43:300-309.
5. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
6. Fukuda, H., M. Hosaka, S. Iyobe, N. Gotoh, T. Nishino, and K. Hirai. 1995. nfxC-type quinolone resistance in a clinical isolate of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:790-792.
7. Gotoh, N., N. Itoh, H. Tsujimoto, J. Yamagishi, Y. Oyamada, and T. Hishino. 1994. Isolation of OprM-deficient mutants of Pseudomonas aeruginosa by transposon insertion mutagenesis: evidence of involvement in multiple antibiotic resistance. FEMS Microbiol. Lett. 122:267-273.
8. Gotoh, N., H. Tsujimoto, M. Tsuda, K. Okamoto, A. Nomura, T. Wada, M. Nakahashi, and T. Nishino. 1998. Characterization of the MexC-MexD-OprJ multidrug efflux system in ΔmexA-mexB-oprM mutants of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 42:1938-1943.
9. Kohler, T., M. Michea-Hamzehpour, U. Henze, N. Gotoh, L. K. Curty, and J. C. Pechere. 1997. Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol. Microbiol. 23:345-354.
10. Lee, A., W. Mao, M. Warren, A. Mistry, K. Hoshino, R. Okumura, H. Ishida, and O. Lomovskaya. 2000. Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance. J. Bacteriol. 182:3142-3150.
11. Lomovskaya, O., A. Lee, K. Hoshino, H. Ishida, A. Mistry, M. S. Warren, E. Boyer, S. Chamberland, and V. J. Lee. 1999. Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43:1340-1346.
12. Lomovskaya, O., M. S. Warren, A. Lee, J. Galazzo, R. Fronko, M. Lee, J. Blais, D. Cho, S. Chamberland, T. Renau, R. Leger, S. Hecker, W. Watkins, K. Hoshino, H. Ishida, and V. J. Lee. 2001. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob. Agents Chemother. 45:105-116.
13. 50) and its error with a small computer. J. Toxicol. Environ. 3:797-809.
14. Poole, K., N. Gotoh, H. Tsujimoto, Q. Zhao, A. Wada, T. Yamasaki, S. Neshat, J. Yamagishi, X. Z. Li, and T. Nishino. 1996. Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa. Mol. Microbiol. 21:713-724.
15. Poole, K., K. Krebes, C. McNally, and S. Neshat. 1993. Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J. Bacteriol. 175:7363-7372.
16. Teng, N. H., H. S. Kaplan, J. M. Herbert, C. Moore, H. Douglas, A. Wunderlich, and A. I. Braude. 1975. Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc. Natl. Acad. Sci. USA 82:1790-1794.
17. Yoneyama, H., A. Ocaktan, M. Tsuda, and T. Nakae. 1997. The role of mex-gene products in antibiotic extrusion in Pseudomonas aeruginosa. Biochem. Biophys. Res. Commun. 233:611-618.
18. Yoshida, T., T. Muratani, S. Iyobe, and S. Mitsuhashi. 1994. Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 38:1466-1469.